Comparing the current results to its competitors, Establishment Labs Holdings Inc reported Revenue increase in the 2 quarter 2026 by 31.73 % year on year. The sales growth was above Establishment Labs Holdings Inc 's competitors' average revenue growth of 6.47 %, achieved in the same quarter.
Establishment Labs Holdings Inc , faster than the decline experienced by the competitors of -0 %. recorded a net loss, despite income increase by most of its competitors of -0 %
Establishment Labs Holdings Inc 's Comment on Competition and Industry Peers
The silicone breast implant market in the United States includes three primary competitors: Sientra, Allergan, and Mentor. Each company has conducted 10-year prospective Core clinical trials reporting adverse event rates such as rupture, capsular contracture, and reoperation. Reported rupture rates were 8.5% for Sientra, 9.3% for Allergan, and 24.2% for Mentor. Capsular contracture rates were 12.9% for Sientra, 18.9% for Allergan, and 12.1% for Mentor. Reoperation rates were 24.0% for Sientra, 36.1% for Allergan, and 25.5% for Mentor. These data were released in 2018 for Sientra and Allergan, and in 2015 for Mentor. Motiva Implants, registered in over 100 countries and recently approved by the U.S. FDA, report lower rates of adverse events and improved safety and aesthetic outcomes, attributed to proprietary technologies including the SmoothSilk surface and ProgressiveGel family. The company seeks to expand its market share by addressing patient concerns regarding safety and natural appearance.
October 31, 2024
In an era where women s health and wellness have become focal points in medical innovation, Establishment Labs Holdings Inc. continues to make significant strides in the domain of breast aesthetics and reconstruction. The company recently garnered attention at the 9th Annual World Symposium on Ergonomic Implants (WSEI) held in Barcelona, Spain, where it unveiled three-year clinical results from its groundbreaking Mia Femtech study. This prospective, Institutional Review Board (IRB)-approved study involved 100 subjects and has provided valuable insights into the efficacy and safety of the Mia Femtech technology, further solidifying Establishment Labs commitment to advancing female healthcare.The Mia Femtech ...
January 2, 2024
Establishment Labs Holdings Inc., a global leader in medical technology, recently achieved a groundbreaking milestone in breast aesthetics and reconstruction. The company proudly announced that the Motiva Flora SmoothSilk Tissue Expander, known for its innovative design and superior performance, was successfully utilized for the first time in the United States. This pivotal moment took place at the esteemed University of Texas MD Anderson Cancer Center in Houston, under the skilled hands of Professor Mark Clemens, MD MBA FACS, a renowned expert in plastic surgery.The Motiva Flora SmoothSilk Tissue Expander, which received recent clearance from the U.S. Food and Drug Administration (FDA), is set to revolution...
Publicly Traded Peers of Establishment Labs Holdings Inc
Venus Concept Inc Share Performance
-97.47%
One Year
Venus Concept Inc
Profile
Venus Concept Inc's business model focuses on offering innovative and effective medical aesthetic devices and technology solutions to healthcare professionals.
Lucid Diagnostics Inc is a healthcare company that operates with a business model focused on developing and providing innovative diagnostic solutions for the early detection and prevention of diseases, aimed at improving patient outcomes and reducing healthcare costs. They leverage advanced technologies and medical expertise to deliver accurate and reliable diagnostic services to healthcare providers, enabling better decision-making and personalized treatment plans for patients.
Lensar Inc is a medical technology company that operates through a business model focused on the development and commercialization of advanced laser systems for ophthalmic procedures. They aim to provide innovative solutions to healthcare professionals in order to enhance precision, safety, and efficiency in eye surgeries.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Iridex Corp's business model revolves around providing advanced medical devices and solutions for the treatment of eye conditions, primarily focused on ophthalmology.
Sources:
Establishment Labs Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Establishment Labs Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
